Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

The method of claim 6, wherein between about 0.05 and about 10 μg/eye of a compound of formula (I) is administered.

A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in primates, comprising topically a therapeutically effective amount of a compound of formula:

• 16
• wherein R1=hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C1-C12 alkyl cycloalkyl or aryl;
• and R2=Cl or CF3.

A method of treating glaucoma and ocular hypertension, which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:

• 17
• wherein R1=a pharmaceutically acceptable ester moiety;
• and R2=Cl or CF3.

A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of cyclopentane heptenoic acid, 5-cis-2-(3-α-hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5-dihydroxy 1α,2β,3α,5α].

A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of fluprostenol.

A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in humans, comprising a therapeutically effective amount of fluprostenol.

A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:

• 14
• wherein R1=hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C1-C12 alkyl cycloalkyl or aryl;
• and R2=Cl or CF3.

A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in primates, comprising topically a therapeutically effective amount of a compound of formula:

• 15
• wherein R1=hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C1-C12 alkyl cycloalkyl or aryl;
• and R2=Cl or CF3.

A method of treating glaucoma and ocular hypertension, which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:

• 18
• wherein R1=a pharmaceutically acceptable ester moiety;
• and R2=C1 or CF3.

A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of cyclopentane heptenoic acid, 5-cis-2-(3-a-hydroxy-4-m-chlorophenoxy-1-trans-butenyl)-3,5-dihydroxy 1α,2β,3α,5α].

A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of fluprostenol.

A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in humans, comprising a therapeutically effective amount of fluprostenol.